Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid …

TP Das, D North, SA Fleming, JLC Tan, A Ivey… - … and Cellular Therapy, 2023 - Elsevier
Monitoring of donor chimerism (DC) may detect early relapse following allogeneic
hematopoietic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) or …
被引用次数：1 相关文章

Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid …

TP Das, D North, SA Fleming, JLC Tan… - Transplantation and …, 2023 - research.monash.edu
Monitoring of donor chimerism (DC) may detect early relapse following allogeneic
hematopoietic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) or …

Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid …

TP Das, D North, SA Fleming… - Transplantation …, 2023 - pubmed.ncbi.nlm.nih.gov
Monitoring of donor chimerism (DC) may detect early relapse following allogeneic
hematopoietic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) or …
[HTML] astctjournal.org

[HTML][HTML] Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute …

TP Das, D North, SA Fleming, JLC Tan… - … and Cellular Therapy …, 2023 - astctjournal.org
Monitoring of donor chimerism (DC) may detect early relapse following allogeneic
hematopoietic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) or …